Charles Davis, PhD

Charles Davis, PhDClinical Pharmacology

Charles Davis, Senior Vice President of Clinical Pharmacology, is a core member of the Tango team developing TNG908, our MTA-cooperative PRMT5 inhibitor, and has overseen the IND enabling DMPK and Safety studies for Tango’s first 3 IND submissions.

Prior to joining Tango, Charles was Vice President, PK Sciences (PKS) at Novartis Institutes for BioMedical Research (NIBR), where he led an international team responsible for the oncology portfolio from discovery through launch. In this role, he was a member of the PKS Leadership Team, the Integrated Cancer Board and the Oncology Development Leadership Team. Before joining Novartis in 2013, Charles spent more than 20 years at GlaxoSmithKline, where he served on the leadership teams of three of GSK’s Centers of Excellence in Drug Discovery. Charles and his teams have contributed to the development of 19 marketed drugs.

Charles has a Bachelor of Arts in chemistry from Swarthmore College and a doctorate in biophysical chemistry from Cornell University.